Professor Andrew Tutt

Andrew Tutt qualified in Medicine in 1990. After completing postgraduate training in General Medicine, he trained in Clinical Oncology at the Royal Marsden Hospital, before gaining a Predoctoral Research Training Fellowship from the Medical Research Council to work in Professor Alan Ashworth’s laboratory, at The Institute of Cancer Research. There he worked on the then unknown DNA repair functions of the BRCA2 breast cancer predisposition gene, and described the role of BRCA2 in homologous recombination (HR). He was awarded his PhD in 2002. In his postdoctoral work as a Clinician Scientist, he identified the synthetic lethality between PARP inhibitors and BRCA1/2 mutations with Dr Chris Lord and Professor Alan Ashworth. He went on to design the single agent PARP inhibitor Proof of Concept Phase I trials and associated DNA repair biomarker studies with the ICR and Royal Marsden Drug Development Unit, and has since led international Phase II and III trials, examining the role of HR directed therapies, including PARP inhibitors and platinums for BRCA1 / BRCA2 deficiency associated malignancy including; the OlympiA and TNT trials, which have changed clinical practice guidelines for patients with BRCA1 and BRCA2 mutated breast cancer. He cares for women with breast cancer as a Consultant Oncologist, and as a member of the multidisciplinary Breast Units at Guy’s and St Thomas’ and Royal Marsden NHS Foundation Trusts. Andrew has been a member of the St Gallen Early Breast Cancer International Consensus Panel, the Oxford Early Breast Cancer Trialists Cooperative Group (EBCTCG) and Vice Chair of CRUK Experimental Medicine Expert Review Panel. He is a member of ESMO Breast Cancer Guidelines and serves on the ESMO Scientific Committees shaping the programmes for both ESMO Breast 2022 and ESMO 2023 congresses. He is Director of the Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research (ICR) and the Breast Cancer Now Research Unit at King’s College London (KCL). He is Head of the Division of Breast Cancer Research and Professor of Breast Oncology at the ICR and a Professor of Clinical Oncology at KCL. Andrew leads a clinical trial programme focusing on TNBC and cancers associated with functional deficiencies in BRCA1 and BRCA2. He also leads translational laboratories at both the ICR and KCL, studying BRCA1 and BRCA2 associated and Triple Negative forms of breast cancer (TNBC). His ICR laboratory is joint with biologist colleague Professor Christopher Lord. In 2015 he received the Addarii Award from the University of Bologna for his work in the field of BRCA1 and BRCA2 associated breast and ovarian cancer research. In 2019 Andrew was elected to the Fellowship of the Academy of Medical Sciences and most recently was awarded the ESMO Breast Cancer Award 2021.